Study Of Patients With Allergic Rhinitis And Asthma

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Fluticasone; Fluticasone Propionate, Salmeterol Xinafoate Drug Combination; Fluticasone-Salmeterol Drug Combination; Montelukast; Salmeterol Xinafoate; Xhance

Criteria

Inclusion Criteria:

• Have asthma for at least 3 months prior to the study.

• Have been using an allowed pre-study asthma therapy for at least 3 months prior to study.

• Currently have seasonal allergic rhinitis and have had seasonal onset of allergic rhinitis for at least the two previous allergy seasons.

• Have a positive allergy skin test.

Exclusion Criteria:

• Have a history of life-threatening asthma.

• Been hospitalized for asthma within the 6 months prior to the study.

• Have certain conditions that would make study participation unsafe.

The study doctor will evaluate other inclusion and exclusion criteria.